Definium Therapeutics shares are trading higher. The company announced results from a healthcare claims study on treatment patterns in Generalized Anxiety Disorder patients.

Benzinga Newsdesk www.benzinga.com Positive 68.4%

Neg 0% Neu 0% Pos 68.4%

Comments

No comments yet. Be the first!